Australia markets closed

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541.HK)

HKSE - HKSE Delayed price. Currency in HKD
Add to watchlist
13.820-0.040 (-0.29%)
At close: 04:08PM HKT
Show:
Balance sheet
Cash flow
Annual

Income statement

Currency in CNY. All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
Total revenue
386
386
538
5,067
Operating expenses
Research development
291,944
291,944
277,346
175,954
Selling general and administrative
80,424
80,424
92,796
48,319
Total operating expenses
365,059
365,059
364,990
215,532
Operating income or loss
-364,673
-364,673
-364,452
-210,465
Interest expense
1,524
1,524
787
891
Income before tax
-379,459
-379,459
-402,894
-732,949
Income tax expense
0
0
0
0
Income from continuing operations
-379,459
-379,459
-402,894
-732,949
Net income
-379,459
-379,459
-402,894
-732,949
Net income available to common shareholders
-379,459
-379,459
-402,894
-732,949
Basic EPS
-0.97
-1.05
-1.08
-1.96
Diluted EPS
-0.97
-1.05
-1.08
-1.96
Basic average shares
373,240
361,810
373,240
373,240
Diluted average shares
373,240
361,810
373,240
373,240